BeOne Medicines (ONC) announced that the European Commission has approved a new film-coated tablet formulation of Brukinsa – zanubrutinib – for all approved indications. The Brukinsa tablets are 160 mg each, allowing patients to halve their daily pill intake from four pills to two. Additionally, they are smaller than the capsules and have film coatings, which make them easier to swallow. Brukinsa is designed to deliver complete and sustained inhibition of the BTK protein and has been demonstrated to inhibit the proliferation of malignant B cells within a number of disease-relevant tissues.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines: Strong Financial Performance and Promising Pipeline Drive Buy Rating
- BeOne Medicines price target raised to $350 from $340 at BofA
- BeOne Medicines price target raised to $360 from $334 at TD Cowen
- BeOne Medicines: Strong Financial Performance and Strategic Positioning Justify Buy Rating
- BeOne Medicines Reports Strong Q2 2025 Performance